- ►annals.org M Banikazemi, J Bultas, S Waldek, WR Wilcox … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Fabry disease ( -galactosidase A deficiency) is a rare, X-linked
lysosomal storage disorder that can cause early death from renal, cardiac, and
cerebrovascular involvement. ... Objective: To see whether agalsidase beta ... Cited by 134 - Related articles - BL Direct - All 6 versions
- ►asnjournals.org DP Germain, S Waldek, M Banikazemi, DA … - Journal of the American Society of Nephrology, 2007 - Am Soc Nephrol Fabry disease, an inherited deficiency of the lysosomal enzyme -galactosidase A,
causes progressive intralysosomal accumulation of globotriaosylceramide (GL-3)
and premature death from renal, cardiac, and cerebrovascular ... Cited by 92 - Related articles - All 6 versions
F Breunig, F Weidemann, J Strotmann, A … - Kidney international, 2006 - nature.com Enzyme replacement therapy (ERT) with recombinant human -galactosidase A (rh
GalA) enhances microvascular globotriaosylceramide clearance and improves
clinical symptoms in patients with Fabry disease. We evaluated whether ... Cited by 67 - Related articles - BL Direct - All 4 versions
- ►oxfordjournals.org R Schiffmann, M Ries, M Timmons, JT … - Nephrology Dialysis Transplantation, 2006 - ERA-EDTA Results. During the 4–4.5 years of enzyme replacement therapy, all eligible
subjects were able to transition to home therapy. Eight patients developed
persistent IgG antibodies to agalsidase alfa, but IgE antibodies were not ... Cited by 95 - Related articles - BL Direct - All 6 versions
- ►angrylapdog.com R Schiffmann, H Askari, M Timmons, C … - Journal of the American Society of Nephrology, 2007 - jasn.org.p.angrylapdog.com This study was performed to determine whether adult male patients with Fabry
disease who demonstrate a continuing decline in renal function despite 2 to 4 yr
of conventionally dosed agalsidase alfa therapy (0.2 mg/kg every other week ... Cited by 42 - Related articles - All 8 versions
- ►nih.gov WR Wilcox, M Banikazemi, N Guffon, S Waldek … - The American Journal of Human Genetics, 2004 - Elsevier Elsewhere, we reported the safety and efficacy results of a multicenter phase 3
trial of recombinant human α-galactosidase A (rh-αGalA) replacement in
patients with Fabry disease. All 58 patients who were enrolled in the 20-wk ... Cited by 201 - Related articles - BL Direct - All 12 versions
- ►asn-online.org [PDF] - Free from Publisher H Tahir, LL Jackson, DG Warnock - Journal of the American Society of Nephrology, 2007 - Am Soc Nephrol This report describes an open-label, nonrandomized, prospective evaluation of
the effects of angiotensin-converting enzyme inhibitor and angiotensin receptor
blocker therapy on patients who have Fabry disease and also received enzyme ... Cited by 34 - Related articles - All 8 versions
GE Linthorst, CEM Hollak, WE Donker-Koopman … - Kidney international, 2004 - nature.com Gabor Linthorst and Carla Hollak have been involved in the phase III clinical
study with agalsidase beta. The authors do not serve as consultants to, hold
stock in, or receive money from Genzyme Corp. or TKT, Inc. Cited by 76 - Related articles - BL Direct - All 5 versions
CM Eng, J Fletcher, WR Wilcox, S Waldek, CR … - Journal of inherited metabolic disease, 2007 - Springer J Inherit Metab Dis (2007) 30:184–192 DOI 10.1007/s10545-007-0521-2 ... Fabry
disease: Baseline medical characteristics of a cohort of 1765 ... CM Eng · J.
Fletcher · WR Wilcox · S. Waldek · CR Scott · DO Sillence · F. Breunig ... Cited by 57 - Related articles - BL Direct - All 5 versions
CM Eng, DP Germain, M Banikazemi, DG … - Genetics in Medicine, 2006 - journals.lww.com From the 1 Baylor College of Medicine, Houston, Texas; 2 Hôpital Européen
Georges Pompidou, Paris, France; 3 Mount Sinai School of Medicine, New York, New
York; 4 University of Alabama at Birmingham, Birmingham, Alabama; 5 ... Cited by 74 - Related articles - BL Direct - All 3 versions
